Jul 2026· Clinical Medicine Advances· Vol 1, pp. 1-2· 0 citations
TL;DR
The translation from mechanistic insight to durable bedside impact remains uneven across disciplines, and the gap between molecular and immunological discovery on one side, and real-world clinical practice on the other is precisely why Clinical Medicine Advances was founded.
Abstract
In the past decade, clinical medicine has witnessed a striking acceleration. CAR-T and engineered cell therapies have moved from oncology into autoimmune indications such as systemic lupus erythematosus and idiopathic inflammatory myopathies; next-generation antibody therapeutics, targeted protein degraders, and precision immunomodulators are reshaping both tumor control and immune tolerance. And yet, the translation from mechanistic insight to durable bedside impact remains uneven across disciplines. This gap, between molecular and immunological discovery on one side, and real-world clinical practice on the other, is precisely why Clinical Medicine Advances (CMA) was founded.
Current active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3.
S. Schokrpur, M. G. White, C. Roland et al.· Hematology/Oncology Clinics...· 0 citations
“As a physician, my goal is to develop a therapy that all intended patients, and healthcare systems, can afford and deliver.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with Dr Frank Borriello, CEO, Alloplex Biotherapeutics, about a non-engineered, autologous approach to cancer immunother...
Frank Borriello· Cell and Gene Therapy Insigh...· 0 citations
The treatment of inflammatory skin diseases has moved from broad immunosuppression toward mechanism‐based therapy with targeted biologics and small molecules. Psoriasis exemplifies this shift: interleukin‐23 (IL‐23)/T helper 17 (Th17) blockade can achieve near‐complete clearance, yet persistent tissue‐resident memory T...
L. Kemény· International Journal of Der...· 0 citations
Despite advances in traditional therapies, the global burden of malignant tumors remains substantial. Although immunotherapy has achieved remarkable breakthroughs by activating the host immune system, its clinical benefits are limited to a subset of patientsowing to low response rates and drug resistance. Emerging evid...
Hao-Juan Feng, Xiu-Juan Huang, Yong-Ju Zhuang et al.· Frontiers in Immunology· 0 citations
A cell therapy safety signal defined the month: Novartis paused eight trials of its experimental CAR-T therapy rap-cel across autoimmune and neurological indications after three deaths from immune effector cell-associated hemophagocytic syndrome, prompting Bristol Myers Squibb to pause a rival program as a precaution....
Abigail Pinchbeck· Cell and Gene Therapy Insigh...· 0 citations
To review the principles, mechanisms, clinical applications, safety considerations, challenges and future perspectives of theranostics. Literature from peer-reviewed journals, clinical trials and authoritative sources was reviewed. Theranostics integrates molecular imaging and targeted therapy, demonstrating significan...
Sanjeyan N., Y. C, N. Kumar S. et al.· International Journal of Res...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
